Literature DB >> 33180662

Primary squamous cell carcinoma of the breast: report of two cases with HER2 overexpression.

Ruixue Lei1, Lanfang Miao1.   

Abstract

OBJECTIVE: To investigate the clinicopathologic features and immunophenotype of primary squamous cell carcinoma of the breast (PSCCB) with HER2 overexpression. Methods Two cases of PSCCB with HER2 overexpression were retrospectively reviewed, and the pathological features, immunophenotype and prognosis were discussed. Results The tumor showed malignant squamous cells arranged in sheets, groups and nests, forming keratin-pearl and intercellular bridges. Immunohistochemical (IHC) analysis showed that the tumor cells were positive for 34βE12, p63, CK5/6, E-cadherin and P120, while negative for ER and PR. Furthermore, HER2 overexpression showed strong continuous expression in cell membrane with a score of 3+ by IHC, or amplification by FISH. Conclusions PSCCB is a rare tumor in breast cancer and HER2 overexpression is rather unusual in PSCCB. The diagnosis mainly depends on the clinicopathologic features together with the immunophenotype. HER2 positive indicates poor prognosis. However, targeted therapy for HER2 may be a new hope for patients.

Entities:  

Keywords:  HER2; Primary squamous cell carcinoma; breast

Year:  2020        PMID: 33180662      PMCID: PMC7747679          DOI: 10.1080/15384047.2020.1838033

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  20 in total

1.  Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

Authors:  David B Agus; Robert W Akita; William D Fox; Gail D Lewis; Brian Higgins; Paul I Pisacane; Julie A Lofgren; Charles Tindell; Douglas P Evans; Krista Maiese; Howard I Scher; Mark X Sliwkowski
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

2.  Extremely well differentiated squamous cell carcinoma of the breast. Report of a case with a comparative study of an epidermal cyst.

Authors:  T Motoyama; H Watanabe
Journal:  Acta Cytol       Date:  1996 Jul-Aug       Impact factor: 2.319

3.  Squamous cell carcinoma of the breast.

Authors:  Bryan T Hennessy; Savitri Krishnamurthy; Sharon Giordano; Thomas A Buchholz; Shu W Kau; Zhigang Duan; Vicente Valero; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

4.  Squamous cell carcinoma of the breast: a review of 177 cases.

Authors:  Julia Grabowski; Sidney L Saltzstein; Georgia Sadler; Sarah Blair
Journal:  Am Surg       Date:  2009-10       Impact factor: 0.688

Review 5.  Pertuzumab: new hope for patients with HER2-positive breast cancer.

Authors:  M Capelan; L Pugliano; E De Azambuja; I Bozovic; K S Saini; C Sotiriou; S Loi; M J Piccart-Gebhart
Journal:  Ann Oncol       Date:  2012-08-21       Impact factor: 32.976

6.  Pure primary squamous cell carcinoma of the breast: a rare presentation and clinicopathologic comparison with usual ductal carcinoma of the breast.

Authors:  Chakshu Gupta; Ashok K Malani; Robert T Weigand; Guatam Rangineni
Journal:  Pathol Res Pract       Date:  2006-02-23       Impact factor: 3.250

7.  Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.

Authors:  Mary C Schroeder; Priya Rastogi; Charles E Geyer; Lance D Miller; Alexandra Thomas
Journal:  Oncologist       Date:  2018-01-12

8.  Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype.

Authors:  Ruohong Shui; Anqi Li; Fei Yang; Xiaoyan Zhou; Baohua Yu; Xiaoli Xu; Wentao Yang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

9.  Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.

Authors:  J M Del Campo; R Hitt; P Sebastian; C Carracedo; D Lokanatha; J Bourhis; S Temam; D Cupissol; D De Raucourt; N Maroudias; C M Nutting; N Compton; D Midwinter; L Downie; N Biswas-Baldwin; I El-Hariry; K J Harrington
Journal:  Br J Cancer       Date:  2011-08-09       Impact factor: 7.640

10.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.